Companies ›Healthcare ›PRPO.O

PRPO.O — NASDAQ Healthcare Equipment

Precipio Inc

$22,13

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

39,5M USD

P/E

—

EV / Rev

2,1x

Div yield

—

Op margin

-60,4 %

ROE

-16,3 %

Net margin

-60,6 %

Debt / equity

0,03

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$23,34

Open

$23,45

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Precipio Inc provides diagnostic and genomic testing services to healthcare providers, primarily in the United States.

Business. Precipio Inc (PRPO.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupHealthcare Equipment

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

-16,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning PRPO.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to PRPO.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Precipio Inc (PRPO.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupHealthcare Equipment

AI synthesis

GENERATED

Precipio Inc has a market capitalization of $51.05 million and a price-to-book ratio of 4.0, indicating a premium valuation relative to its book value. The company's liquidity position is weak, with a current ratio of 0.78, suggesting that it may struggle to meet short-term obligations with its current assets. Additionally, the company reported negative operating and free cash flows of $667,000 and $1.76 million, respectively, indicating a lack of cash generation from operations.

The company's profitability is underperforming, with a return on equity of -16.28% and a return on assets of -12.51%, both significantly below the industry median for Advanced Medical Equipment & Technology. The negative net income of $2.08 million and operating income of $2.07 million further highlight the company's financial challenges. These metrics suggest that the company is not generating sufficient returns to justify its capital structure or to compete effectively in its industry.

Precipio Inc's revenue is concentrated in the United States, with no disclosed international operations. The company's business is primarily driven by its diagnostic and genomic testing services, which are offered to healthcare providers. There is no indication of significant diversification across product lines or geographic regions.

The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The lack of positive operating cash flow and the negative net income suggest that the company is not currently expanding its operations or increasing its market share. The company's financial performance indicates a need for strategic adjustments to improve profitability and cash flow generation.

The risk assessment for Precipio Inc indicates a low level of liquidity and dilution risk. However, the company's negative operating and free cash flows, along with its low current ratio, suggest that it may face liquidity challenges in the near term. The company has not disclosed any immediate filing-based liquidity or dilution flags, but its financial performance indicates a need for careful monitoring of its capital structure and cash flow management.

Recent events and filings for Precipio Inc do not indicate any significant changes in the company's financial or operational status. The company's latest financial report shows continued losses and negative cash flows, which may impact its ability to sustain operations without additional financing. There are no disclosed recent events that would significantly alter the company's risk profile or financial outlook.

Key takeaways

Precipio Inc is trading at a price-to-book ratio of 4.0, indicating a premium valuation relative to its book value.
The company's return on equity of -16.28% and return on assets of -12.51% are significantly below the industry median for Advanced Medical Equipment & Technology.
Precipio Inc has a current ratio of 0.78, suggesting potential liquidity challenges in meeting short-term obligations.
The company reported negative operating and free cash flows of $667,000 and $1.76 million, respectively, indicating a lack of cash generation from operations.
The risk assessment for Precipio Inc indicates a low level of liquidity and dilution risk, but the company's financial performance suggests a need for careful monitoring of its capital structure and cash flow management.

Bull / Bear case

Generated · model-assisted

BULL CASE · 4

Revenue surged 58.2% year-over-year to $24.0 million, demonstrating strong top-line growth momentum in the latest fiscal period.

Free cash flow turned positive at $799,000, marking a 117.4% improvement and signaling improved operational cash generation capabilities.

Gross profit expanded to $10.7 million, reflecting improved cost of goods sold management and higher margin efficiency on sales.

The company maintains a low leverage band with a debt-to-equity ratio of 0.0053, minimizing financial risk and interest obligations.

BEAR CASE · 3

Cash conversion ratio is in the bottom quartile at 0.32, lagging the cohort median of 0.79, suggesting weak cash generation relative to earnings.

The company carries a high credit risk flag, potentially limiting access to favorable financing terms despite low current debt levels.

Institutional ownership is negligible with top holders controlling less than 0.01% of shares, indicating a lack of significant institutional confidence.

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2024-03-29

Q4 2023 · Quarter highlights

Revenue $4.4M; Operating income -$1.2M.

Revenue$4.4M

Operating income-$1.2M

Net income-$1.2M

Free cash flow-$906.0k

EPS—

Operating cash flow-$167.0k

Financials

Income statement

Revenue$4.4M

Gross profit$1.7M

Operating income-$1.2M

Net income-$1.2M

Margins

Gross margin38.6%

Operating margin-27.2%

Net margin-27.5%

FCF margin-20.4%

Balance sheet

Total assets$17.3M

Total liabilities$5.2M

Total equity$12.1M

Cash & equivalents$1.3M

Long-term debt$661.0k

Cash flow

Operating cash flow-$167.0k

CapEx-$70.0k

Free cash flow-$906.0k

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue $4.4M
▍Operating income -$1.2M
▍Net margin -27.5%

Valuation FY

Market price

$22,13

Market cap

$51.0M

Enterprise valueⓘ

$50.6M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

2.1x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

4.0x

P / Tangible bookⓘ

4.0x

Tangible book

$12.8M

Net cashⓘ

$411.0k

Current ratioⓘ

0.8

Debt / equityⓘ

0.0

ROAⓘ

-12.5%

ROEⓘ

-16.3%

Cash conversionⓘ

32.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries2

EX21:a87dbd9e66e3EX21:a87dbd9e66e3Subsidiarie97%

EX21:b2a41fe4bbf5EX21:b2a41fe4bbf5Subsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs PRPO · multiples and returns

VEEV—

Veeva Systems Inc

$158,86

25,9B USD

P/E

157,9x

— vs self

Div yield

—

— vs self

ROE

3,3 %

+19,6 vs self

QDEL—

QuidelOrtho Corporation

$17,71

1,2B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-58,9 %

-42,7 vs self

EVH—

Evolent Health, Inc.

$3,14

351,4M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-134,8 %

-118,6 vs self

OMCL—

OMNICELL, INC.

$46,82

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

1,7 %

+17,9 vs self

TBRG—

Trubridge Inc

$26,24

393,6M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-1,0 %

+15,3 vs self

LFMD—

Lifemd Inc

$3,73

177,5M USD

P/E

13,6x

— vs self

Div yield

—

— vs self

ROE

62,0 %

+78,3 vs self

SLP—

SIMULATIONS PLUS, INC.

$18,31

370,5M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-46,6 %

-30,3 vs self

SOPH—

Sophia Genetics SA

$5,80

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-60,4 %Above median

Net Margin-60,6 %Above median

ROE-16,3 %Above median

D/E0,03Below median

Cash Conv0,32Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 44 000 sh9 grants9 insiders

Valauri Christina RizopoulosDirector · Stock Option (Right to Buy) → Common StockAcquired 1 500 @ $23,82grant · 2026-01-02
Sabet Ahmed ZakiChief Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $23,82grant · 2026-01-02
SANDBERG RICHARD ADirector · Stock Option (Right to Buy) → Common StockAcquired 1 500 @ $23,82grant · 2026-01-02
LAPORTE KATHLEENDirector · Stock Option (Right to Buy) → Common StockAcquired 1 500 @ $23,82grant · 2026-01-02
Gage MatthewChief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 5 000 @ $23,82grant · 2026-01-02
DANIELI ILANDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $23,82grant · 2026-01-02
ANDREWS RONALD ASBURYDirector · Stock Option (Right to Buy) → Common StockAcquired 1 500 @ $23,82grant · 2026-01-02
Cohen David SethDirector · Stock Option (Right to Buy) → Common StockAcquired 1 500 @ $23,82grant · 2026-01-02
Cossman JeffreyDirector · Stock Option (Right to Buy) → Common StockAcquired 1 500 @ $23,82grant · 2026-01-02

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue

Source documents

Precipio Inc Market data — financials · 2026-05-29

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

Insider activity

Net selling3 buys · 4 sellsnet -$99K7 insiders · last 365d

SANDBERG RICHARD ADirector · Common StockSold 900 @ $25,02$23K · 2026-05-21
SANDBERG RICHARD ADirector · Common StockSold 500 @ $25,00$12K · 2026-05-20
SANDBERG RICHARD ADirector · Common StockSold 2 034 @ $24,89$51K · 2026-05-20
SANDBERG RICHARD ADirector · Common StockSold 600 @ $24,42$15K · 2026-05-19
Cohen David SethDirector · Common StockOther 445 @ $29,49$13K · 2026-04-15
Valauri Christina RizopoulosDirector · Common StockOther 93 @ $29,49$3K · 2026-04-15
Cossman JeffreyDirector · Common StockOther 365 @ $29,49$11K · 2026-04-15
Sabet Ahmed ZakiChief Operating Officer · Common StockBought 19 @ $27,93$531 · 2026-04-01
LAPORTE KATHLEENDirector · Common StockOther 520 @ $24,00$12K · 2026-01-15
Valauri Christina RizopoulosDirector · Common StockOther 406 @ $24,00$10K · 2026-01-15
Cohen David SethDirector · Common StockOther 546 @ $24,00$13K · 2026-01-15
Cossman JeffreyDirector · Common StockOther 437 @ $24,00$10K · 2026-01-15
Sabet Ahmed ZakiChief Operating Officer · Common StockBought 20 @ $23,40$468 · 2026-01-02
Cossman JeffreyDirector · Common StockOther 597 @ $17,58$10K · 2025-10-15
LAPORTE KATHLEENDirector · Common StockOther 711 @ $17,58$12K · 2025-10-15
Cohen David SethDirector · Common StockOther 746 @ $17,58$13K · 2025-10-15
ANDREWS RONALD ASBURYDirector · Common StockOther 568 @ $17,58$10K · 2025-10-15
Sabet Ahmed ZakiChief Operating Officer · Common StockBought 25 @ $19,50$488 · 2025-10-01

Short positioning

26.4Kshares short-3.9% vs prior

1days to cover

53.4%short of daily vol

756fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

PRPO.OCanonical

NASDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Net income (YoY) (2025-12-31 vs 2024-12-31): 91.5%Derived (calculated)
Return on assets (FY 2025-12-31): -1.7%Derived (calculated)
Gross margin (FY 2025-12-31): 44.5%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 25.4%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 37.8%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 23.1%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 71.5%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 56.0%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -78.3%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 41.6%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 92.2%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 29.8%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 92.2%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 21.6%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 90.9%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 46.2%Derived (calculated)
Current ratio (FY 2025-12-31): 1.61xDerived (calculated)
Net margin (FY 2025-12-31): -1.5%Derived (calculated)
Cash & equivalents (annual): USD 2.65MSEC XBRL filing
R&D expense (annual): USD 1.6MSEC XBRL filing
Gross profit (annual): USD 10.71MSEC XBRL filing
Revenue (annual): USD 24.05MSEC XBRL filing
Operating cash flow (annual): USD 685KSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-06-15FILING8-K filing →

2026-05-21 00:00 UTCINSIDER4 insider transactions — 2026-05 · net sell $100k

2026-05-21INSIDERSANDBERG RICHARD A sold 900 sh — Director ~$23k

2026-05-20INSIDERSANDBERG RICHARD A sold 500 sh — Director ~$12k

2026-05-20INSIDERSANDBERG RICHARD A sold 2.0k sh — Director ~$51k

2026-05-19INSIDERSANDBERG RICHARD A sold 600 sh — Director ~$15k

2026-05-14FILING10-Q filing →

2026-05-06FILINGFORM 8-K →

2026-04-28FILINGDEF 14A filing →

2026-04-15 00:00 UTCINSIDER4 insider transactions — 2026-04

2026-04-15INSIDERCohen David Seth transacted 445 sh — Director ~$13k

2026-04-15INSIDERValauri Christina Rizopoulos transacted 93 sh — Director ~$3k

2026-04-15INSIDERCossman Jeffrey transacted 365 sh — Director ~$11k

2026-04-01INSIDERSabet Ahmed Zaki bought 19 sh — Chief Operating Officer ~$1k

2026-03-30FILING10-K filing →

2026-02-27FILINGFORM 8-K →

2026-01-15 00:00 UTCINSIDER14 insider transactions — 2026-01 9 derivative

2026-01-15INSIDERLAPORTE KATHLEEN transacted 520 sh — Director ~$12k

2026-01-15INSIDERValauri Christina Rizopoulos transacted 406 sh — Director ~$10k

2026-01-15INSIDERCohen David Seth transacted 546 sh — Director ~$13k

2026-01-15INSIDERCossman Jeffrey transacted 437 sh — Director ~$10k

2026-01-02INSIDERSabet Ahmed Zaki bought 20 sh — Chief Operating Officer ~$0k

2026-01-02INSIDERLAPORTE KATHLEEN acquired 1.5k sh Stock Option (Right to Buy) — Director

2026-01-02INSIDERDANIELI ILAN acquired 15.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer

2026-01-02INSIDERGage Matthew acquired 5.0k sh Stock Option (Right to Buy) — Chief Financial Officer

2026-01-02INSIDERValauri Christina Rizopoulos acquired 1.5k sh Stock Option (Right to Buy) — Director

2026-01-02INSIDERSabet Ahmed Zaki acquired 15.0k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-01-02INSIDERSANDBERG RICHARD A acquired 1.5k sh Stock Option (Right to Buy) — Director

2026-01-02INSIDERANDREWS RONALD ASBURY acquired 1.5k sh Stock Option (Right to Buy) — Director

2026-01-02INSIDERCohen David Seth acquired 1.5k sh Stock Option (Right to Buy) — Director

2026-01-02INSIDERCossman Jeffrey acquired 1.5k sh Stock Option (Right to Buy) — Director

2025-12-29FILINGFORM 8-K →

2025-11-14FILING10-Q filing →

2025-11-06FILINGFORM 8-K →

2025-10-15 00:00 UTCINSIDER5 insider transactions — 2025-10

2025-10-15INSIDERCossman Jeffrey transacted 597 sh — Director ~$10k

2025-10-15INSIDERLAPORTE KATHLEEN transacted 711 sh — Director ~$12k

2025-10-15INSIDERCohen David Seth transacted 746 sh — Director ~$13k

Showing the 40 most recent of 51 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread